文献速递免疫规划卫生政策与健康促进

孟加拉国青春期女孩接种两剂双价(Cervarix)和四价(Gardasil)HPV疫苗的成本效果

Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
PubMed 文献 · Vaccine · 2019-10-24

研究使用PRIME模型评估孟加拉国引入两剂双价和四价HPV疫苗的成本效果。以Gavi谈判价格引入双价疫苗具有高度成本效果(ICER=488美元/DALY),但两种疫苗按标价均不具成本效果。疫苗价格是成本效果的主要决定因素。

要点

  • 以Gavi谈判价格引入两剂双价HPV疫苗具有高度成本效果(ICER=488美元/DALY)。
  • 按标价双价和四价疫苗均不具成本效果(ICER分别为1405和3250美元/DALY)。
  • 疫苗价格是双价和四价疫苗成本效果的主导参数。

核心结论

  • 在孟加拉国以Gavi谈判价格引入两剂双价HPV疫苗接种项目具有成本效果。
  • 疫苗价格是双价和四价疫苗成本效果的主导参数,两种疫苗按标价在孟加拉国均不具成本效果。
  • 评估表明,以Gavi谈判价格将两剂双价HPV疫苗纳入孟加拉国国家免疫规划在经济上可行,可减轻宫颈癌负担。

研究设计与样本

  • 研究使用Papillomavirus Rapid Interface for Modelling and Economics(PRIME)模型评估引入HPV疫苗接种的成本效果。
  • 以每避免一个伤残调整生命年(DALY)的增量成本效果比(ICER)进行估计,使用成本效果阈值(CET)。
  • 分析从卫生系统角度、按疫苗递送途径进行。

主要发现

  • 以Gavi谈判价格引入双价HPV疫苗接种具有高度成本效果(ICER=488美元/DALY)。
  • 按学校、卫生机构和外展项目为基础的ICER分别为每避免一个DALY 710美元、356美元和397美元,与CET范围(67至854美元)一致。
  • 双价和四价疫苗按标价的ICER分别为每避免一个DALY 1405美元和3250美元,超过CET值。

关键数值与推荐

  • 双价疫苗以Gavi谈判价格的ICER=488美元/DALY,判定为高度成本效果。
  • 学校为基础项目ICER=710美元/DALY,卫生机构为基础项目ICER=356美元/DALY,外展为基础项目ICER=397美元/DALY,均在CET范围(67至854美元)内。
  • 双价疫苗按标价ICER=1405美元/DALY,四价疫苗按标价ICER=3250美元/DALY,均超过CET值。

临床怎么用

  • 作者认为,以Gavi谈判价格将两剂双价HPV疫苗纳入孟加拉国国家免疫规划在经济上可行,可减轻宫颈癌负担。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical cancer is one of the most prevalent cancers in women caused by the human papillomavirus (HPV) that leads to a substantial disease burden for health systems. Prevention through vaccination can significantly reduce the prevalence of cervical cancer. The objective of this study is to evaluate the potential health and economic impacts of introducing two-dose bivalent (Cervarix) and quadrivalent (Gardasil) HPV vaccines in Bangladesh. METHODS: The study uses the Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model to assess the cost-effectiveness of introducing HPV vaccination. The incremental cost-effectiveness ratios (ICERs) were estimated per disability-adjusted life years (DALYs) averted using the cost-effectiveness threshold (CET). The analyses were done from a health system perspective in terms of vaccine delivery routes. RESULTS: Introduction of bi-valent HPV vaccination was found highly cost-effective (ICER = US$488/DALY) at Gavi (The Vaccine Alliance for Vaccines and Immunizations) negotiated prices. The value of ICERs were US$710, US$356 and US$397 per DALY averted for school-based, health facility-based, and outreach-based programs, respectively, which is consistent with the CET range (US$67 to US$854). However, bivalent and quadrivalent vaccines at listed prices were not found cost-effective, with ICERs of US$1405 and US$3250 per DALY averted, respectively, that exceeds the CETs values. CONCLUSIONS: Introducing a two-dose bi-valent HPV vaccination program is cost-effective in Bangladesh at Gavi negotiated prices. Vaccine price is the dominating parameter for the cost-effectiveness of bivalent and quadrivalent vaccines. Both vaccines are not cost-effective at listed prices in Bangladesh. The evaluation highlights that introducing the two-dose bivalent HPV vaccine at Gavi negotiated prices into a national immunization program in Bangladesh is economically viable to reduce the burden of cervical cancer.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mahumud RA, Gow J, Alam K, et al. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh. Vaccine. 2019. PMID: 31668820. doi:10.1016/j.vaccine.2019.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。